289 related articles for article (PubMed ID: 27040279)
1. Intensified and prolonged therapy comprising cytarabine, vincristine and prednisolone improves outcome in patients with multisystem Langerhans cell histiocytosis: results of the Japan Langerhans Cell Histiocytosis Study Group-02 Protocol Study.
Morimoto A; Shioda Y; Imamura T; Kudo K; Kawaguchi H; Sakashita K; Yasui M; Koga Y; Kobayashi R; Ishii E; Fujimoto J; Horibe K; Bessho F; Tsunematsu Y; Imashuku S
Int J Hematol; 2016 Jul; 104(1):99-109. PubMed ID: 27040279
[TBL] [Abstract][Full Text] [Related]
2. Intensification of induction therapy and prolongation of maintenance therapy did not improve the outcome of pediatric Langerhans cell histiocytosis with single-system multifocal bone lesions: results of the Japan Langerhans Cell Histiocytosis Study Group-02 Protocol Study.
Morimoto A; Shioda Y; Imamura T; Kudo K; Kitoh T; Kawaguchi H; Goto H; Kosaka Y; Tsunematsu Y; Imashuku S;
Int J Hematol; 2018 Aug; 108(2):192-198. PubMed ID: 29594922
[TBL] [Abstract][Full Text] [Related]
3. Clinical and prognostic characteristics of 95 cases of Langerhans cell histiocytosis in children: a single-institute experience from 2013 to 2020.
Tang X; Gao J; Ma ZG; Guo X; Li Q; Wan Z; Sun JJ
Ann Med; 2021 Dec; 53(1):1537-1546. PubMed ID: 34459688
[TBL] [Abstract][Full Text] [Related]
4. Improved outcome in the treatment of pediatric multifocal Langerhans cell histiocytosis: Results from the Japan Langerhans Cell Histiocytosis Study Group-96 protocol study.
Morimoto A; Ikushima S; Kinugawa N; Ishii E; Kohdera U; Sako M; Fujimoto J; Bessho F; Horibe K; Tsunematsu Y; Imashuku S;
Cancer; 2006 Aug; 107(3):613-9. PubMed ID: 16804933
[TBL] [Abstract][Full Text] [Related]
5. [Treatment of children with multiple system Langerhans cell histiocytosis by Japan Langerhans Cell Histiocytosis Study Group Protocol].
Huang JB; Xue HM; Chen YY; Huang K
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2013 Feb; 21(1):146-9. PubMed ID: 23484709
[TBL] [Abstract][Full Text] [Related]
6. Treatment of Langerhans cell histiocytosis with a modified risk-adapted protocol-experience from a tertiary cancer institute in India.
Narula G; Pradhan ND; Arora B; Banavali SD
Pediatr Blood Cancer; 2018 Aug; 65(8):e27028. PubMed ID: 29512864
[TBL] [Abstract][Full Text] [Related]
7. Intensification of treatment with vinca alkaloid does not improve outcomes in pediatric patients with Langerhans cell histiocytosis: results from the JPLSG LCH-12 study.
Morimoto A; Shioda Y; Kudo K; Kanegane H; Imamura T; Koh K; Kosaka Y; Yuza Y; Nakazawa A; Saito AM; Watanabe T; Nakazawa Y
Int J Hematol; 2023 Jul; 118(1):107-118. PubMed ID: 36871086
[TBL] [Abstract][Full Text] [Related]
8. Long-term complete response after treatment with cytarabine, vincristine, and prednisone in an infant with refractory multisystem Langerhans cell histiocytosis.
Cook R; Berkow RL; Kelly DR; Friedman GK
Pediatr Blood Cancer; 2011 Jul; 57(1):180-1. PubMed ID: 21412968
[No Abstract] [Full Text] [Related]
9. Treatment of multisystem Langerhans cell histiocytosis. Results of the DAL-HX 83 and DAL-HX 90 studies. DAL-HX Study Group.
Minkov M; Grois N; Heitger A; Pötschger U; Westermeier T; Gadner H
Klin Padiatr; 2000; 212(4):139-44. PubMed ID: 10994540
[TBL] [Abstract][Full Text] [Related]
10. [Outcome Comparison of Pediatric Langerhans Cell Histiocytosis Treated with Modified DAL-HX83/90 or JLSG-96 Protocol].
Huang JB; Jiang L; Chen C; Xue HM
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2016 Aug; 24(4):1190-5. PubMed ID: 27531798
[TBL] [Abstract][Full Text] [Related]
11. Cytosine-arabinoside, vincristine, and prednisolone in the treatment of children with disseminated Langerhans cell histiocytosis with organ dysfunction: experience at a single institution.
Egeler RM; de Kraker J; Voûte PA
Med Pediatr Oncol; 1993; 21(4):265-70. PubMed ID: 8469221
[TBL] [Abstract][Full Text] [Related]
12. [Clinical manifestations of Langerhans cell histiocytosis with multisystem involvement in 53 children].
Tang JJ; Xu XJ; Wang YC; Bai ST; Wang L; Ni XL; Liu YF
Zhonghua Er Ke Za Zhi; 2021 Jan; 59(1):37-41. PubMed ID: 33397002
[No Abstract] [Full Text] [Related]
13. Egyptian experience in Langerhans cells histiocytosis: frequent multisystem affection and reactivation rates.
Tantawy AAG; Ragab IA; Elsherif NHK; Makkeyah SM; AbdelRaheem HG; Elsantiel HIE
Pediatr Hematol Oncol; 2020 Nov; 37(8):696-706. PubMed ID: 32706277
[No Abstract] [Full Text] [Related]
14. Therapy prolongation improves outcome in multisystem Langerhans cell histiocytosis.
Gadner H; Minkov M; Grois N; Pötschger U; Thiem E; Aricò M; Astigarraga I; Braier J; Donadieu J; Henter JI; Janka-Schaub G; McClain KL; Weitzman S; Windebank K; Ladisch S;
Blood; 2013 Jun; 121(25):5006-14. PubMed ID: 23589673
[TBL] [Abstract][Full Text] [Related]
15. Treatment of children with refractory/relapse high risk langerhans cell histiocytosis with the combination of cytarabine, vindesine and prednisone.
Wang W; Ge J; Ma H; Lian H; Cui L; Zhao Y; Li Z; Wang T; Zhang R
BMC Pediatr; 2024 Jan; 24(1):1. PubMed ID: 38172736
[TBL] [Abstract][Full Text] [Related]
16. Central diabetes insipidus in pediatric patients with Langerhans cell histiocytosis: Results from the JLSG-96/02 studies.
Sakamoto K; Morimoto A; Shioda Y; Imamura T; Imashuku S;
Pediatr Blood Cancer; 2019 Jan; 66(1):e27454. PubMed ID: 30207064
[TBL] [Abstract][Full Text] [Related]
17. Outcome of pediatric patients with Langerhans cell histiocytosis treated with 2 chlorodeoxyadenosine: a nationwide survey in Japan.
Imamura T; Sato T; Shiota Y; Kanegane H; Kudo K; Nakagawa S; Nakadate H; Tauchi H; Kamizono J; Morimoto A
Int J Hematol; 2010 May; 91(4):646-51. PubMed ID: 20361277
[TBL] [Abstract][Full Text] [Related]
18. Relapses of multisystem/multifocal bone Langerhans cell histiocytosis in paediatric patients: Data analysis from the JLSG-96/02 study.
Sakamoto K; Morimoto A; Shioda Y; Imamura T; Imashuku S;
Br J Haematol; 2023 Mar; 200(6):769-775. PubMed ID: 36511451
[TBL] [Abstract][Full Text] [Related]
19. High efficacy of the MACOP-B regimen in the treatment of adult Langerhans cell histiocytosis, a 20 year experience.
Derenzini E; Stefoni V; Pellegrini C; Gandolfi L; Broccoli A; Casadei B; Quirini F; Argnani L; Tonialini L; Zinzani PL
BMC Cancer; 2015 Nov; 15():879. PubMed ID: 26552668
[TBL] [Abstract][Full Text] [Related]
20. [Langerhans-cell histiocytosis (histiocytosis X); 20-year experience in the Emma Kinderziekenhuis, 1969-1988].
Egeler RM; de Kraker J; Voûte PA
Ned Tijdschr Geneeskd; 1993 May; 137(19):955-60. PubMed ID: 8497330
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
